Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5594283 | American Heart Journal | 2017 | 28 Pages |
Abstract
Among extreme risk patients with severe AS, TAVR resulted in large initial health status benefits that were sustained through 3-year follow-up. Although late mortality was high in this population, these findings demonstrate that TAVR offers substantial and durable health status improvements for surviving patients.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Suzanne J. MD MSc, Suzanne V. MD, MHA, Matthew R. MD, MSC, Kaijun PhD, Michael MD, Michael J. MD, James MD, Steven J. MD, David H. MD, Jeffrey J. MD, David J. MD, MSc, US CoreValve Investigators US CoreValve Investigators,